Cargando…
Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK‐dependent mechanisms
Metformin, a well‐known AMPK agonist, has been widely used as the first‐line drug for treating type 2 diabetes. There had been a significant concern regarding the use of metformin in people with cardiovascular diseases (CVDs) due to its potential lactic acidosis side effect. Currently growing clinic...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549498/ https://www.ncbi.nlm.nih.gov/pubmed/36052760 http://dx.doi.org/10.1111/jcmm.17519 |